Dobaño, Carlota, 1969-Sanz Ródenas, HéctorSorgho, HermannDosoo, DavidMpina, MaximilianUbillos, ItziarAguilar, RuthFord, TomDíez-Padrisa, NúriaWilliams, Nana AbaAyestaran, AintzaneTraore, OusmaneNhabomba, Augusto J.Jairoce, Chenjerai Tobias SixpenceWaitumbi, JohnAgnandji, Selidji TodagbeKariuki, SimonAbdulla, SalimAponte, John J.Mordmüller, BenjaminAsante, Kwaku PokuOwusu-Agyei, SethTinto, HalidouCampo, Joseph J.Moncunill Piñas, GemmaGyan, BenValim, ClarissaDaubenberger, Claudia2019-06-122019-06-122019-05-152041-1723https://hdl.handle.net/2445/134962RTS,S/AS01E has been tested in a phase 3 malaria vaccine study with partial efficacy in African children and infants. In a cohort of 1028 subjects from one low (Bagomoyo) and two high (Nanoro, Kintampo) malaria transmission sites, we analysed IgG plasma/serum concentration and avidity to CSP (NANP-repeat and C-terminal domains) after a 3-dose vaccination against time to clinical malaria events during 12-months. Here we report that RTS,S/AS01E induces substantial increases in IgG levels from pre- to post-vaccination (p\xE2\x80\x89<\xE2\x80\x890.001), higher in NANP than C-terminus (2855 vs 1297 proportional change between means), and higher concentrations and avidities in children than infants (p\xE2\x80\x89<\xE2\x80\x890.001). Baseline CSP IgG levels are elevated in malaria cases than controls (p\xE2\x80\x89<\xE2\x80\x890.001). Both, IgG magnitude to NANP (hazard ratio [95% confidence interval] 0.61 [0.48-0.76]) and avidity to C-terminus (0.07 [0.05-0.90]) post-vaccination are significantly associated with vaccine efficacy. IgG avidity to the C-terminus emerges as a significant contributor to RTS,S/AS01E-mediated protection.13 p.application/pdfengcc by (c) Dobaño et al., 2019http://creativecommons.org/licenses/by/3.0/es/Vacuna de la malàriaInfantsAfricansMalaria vaccineChildreninfo:eu-repo/semantics/article2019-05-27info:eu-repo/semantics/openAccess31092823